云南省结直肠癌患者BRAF V600E突变与高危临床病理特征和生存关系的研究  

BRAF- V600E Mutation Associated with High- Risk Clinicopathologic Features and Survival in Colorectal Cancer Patients from Yunnan

作　　者：珠珠[1] 黄鉴[1] 李文亮[1] 陈昌望 洪敏[2] 董坚[2] 

机构地区：[1]昆明医科大学第一附属医院肿瘤治疗中心,云南昆明650032 [2]昆明医科大学第一附属医院肿瘤内科,云南昆明650032

出　　处：《昆明理工大学学报（自然科学版）》2014年第3期89-93,共5页Journal of Kunming University of Science and Technology(Natural Science)

基　　金：云南省社会发展科技计划基金资助项目(2011FB160)

摘　　要：BRAF V600E是结直肠癌中常见的突变位点，约5％～15％的患者携带此位点的突变。本研究应用直接测序方法检测云南省术后经病理确诊的289例结直肠癌患者的正常和肿瘤组织DNA发生BRAF V600E突变情况，并结合临床资料统计分析BRAF V600E突变型患者与高危临床病理特征和预后之间的关系。结果显示，在云南本地结直肠癌289例患者中有10％携带BRAF V600E的突变，且突变型与高危临床病理特征有关。临床随访266例患者中，BRAF V600E突变型患者中位生存期、1年生存率和无疾病生存率低于野生型患者。提示BRAF V600E突变与结直肠癌患者高危临床病理特征和预后有关，可能作为评价结直肠癌患者预测不良预后的一个潜在的分子标志物。The BRAF V600E mutation is the most common genetic alteration found in colorectal carcinoma （CRC）,accounting for about 5%-15%of colorectal carcinomas.Direct sequencing to detect the BRAF V600E mutation has recently become commercially available.From January 2010 to October 2013,289 colorectal cancer patients who underwent surgery in First Affiliated Hospital of Kunming Medical University Hospital are enrolled in this study to examine BRAF V600E mutation associated with high -risk clinicopathologic Features and survival.As the results show,the BRAF V600E mutation is found in 29/289 （10%）colorectal cancer patients from Yunnan.Compared with BRAF wild-type adenocarcinomas,BRAF-mutated adenocarcinomas frequently demonstrate more adverse histopathologic features.The BRAF V600E mutation is associated with high -risk clinicopathologic features and outcomes in CRC patients from Yunnan,which suggests that the BRAF V600E mutation may be a potential prognostic molecular marker in CRC patients.

关 键 词：结直肠癌 BRAF V600E 临床病理特征 无疾病生存率 基因突变 

分 类 号：R735.34[医药卫生—肿瘤]